We convened an international group of experts to standardize definitions of NewOnset Refractory Status Epilepticus (NORSE), Febrile Infection-Related Epilepsy Syndrome (FIRES), and related conditions. This was done to enable improved communication for investigators, physicians, families, patients, and other caregivers. Consensus definitions were achieved via email messages, phone calls, an in-person consensus conference, and collaborative manuscript preparation. Panel members
were from 8 countries and included adult and pediatric experts in epilepsy, electroencephalography (EEG), and neurocritical care. The proposed consensus definitions are as follows: NORSE is a clinical presentation, not a specific diagnosis, in a patient without active epilepsy or other preexisting relevant neurological disorder, with new onset of refractory status epilepticus without a clear acute or active structural, toxic or metabolic cause. FIRES is a subcategory of NORSE, applicable for all ages, that requires a prior febrile infection starting between 2 weeks and 24 hours prior to onset of refractory status epilepticus, with or without fever at onset of status epilepticus. Proposed consensus definitions are also provided for Infantile Hemiconvulsion-Hemiplegia and Epilepsy syndrome (IHHE) and for prolonged, refractory and super-refractory status epilepticus. This document has been endorsed by the Critical Care EEG Monitoring Research Consortium. We hope these consensus definitions will promote improved communication, permit multicenter research, and ultimately improve understanding and treatment of these conditions. To standardize the use of these terms, we convened a multinational expert panel at the occasion of the 6th London-Innsbruck Colloquium on Status Epilepticus and Acute
K E Y W O R D S

Key Points
• We convened an international, multidisciplinary group of experts to develop proposed consensus definitions for NORSE, FIRES, and related conditions and terms. These definitions were endorsed by the Critical Care EEG Monitoring Research Consortium
• NORSE is a clinical presentation, not a specific diagnosis, in a patient without active epilepsy or other preexisting relevant neurological disorder, with new onset of refractory status epilepticus without a clear acute or active structural, toxic or metabolic cause
• FIRES is a subcategory of NORSE, applicable for all ages, that requires a prior febrile infection starting between 2 weeks and 24 hours prior to onset of refractory status epilepticus, with or without fever at onset of status epilepticus
• These consensus definitions should allow improved communications and more effective multicenter research Seizures in Salzburg, Austria (www.statusepilepticus.eu). The panel consisted of 18 experts from 8 countries, most of whom are established status epilepticus investigators and all of whom have a special interest in this topic. Seven panel members are pediatric specialists. The conference was supported by The Norse Institute (www.norseinstitute.org).
| OBJECTIVE
To standardize terminology and agree on working definitions in order to:
• Permit multicenter studies.
• Improve communication for clinical care and research.
• Provide a name for this clinical presentation so that (1) patients and families can learn about it, and (2) caregivers can identify related literature using electronic literature searches.
• Improve early recognition of NORSE/FIRES to help with early management and identification of more specific diagnoses. This requires using practical terms that can be applied early in the clinical course; thus, the definitions must not require extensive etiologic testing that may take weeks to complete.
• Help with fundraising for research.
• Avoid conflicting with any existing consensus definitions or guidelines whenever possible, including the status epilepticus classification developed by the International League Against Epilepsy (ILAE). 19 
| METHODS
An initial draft was created by the medical advisory board of The Norse Institute (www.norseinstitute.org; co-chairs: authors LJH and NG). This was followed by extensive email discussions with the full panel, followed by a face to face meeting of 9 members (4 pediatric: AvB, RN, TL, NS; and 5 adult: LJH, NG, SD, VN, ET) from 6 countries in Salzburg, Austria on April 5th, 2017. The definitions were then presented in an open half-day symposium on the same day, with additional edits and clarifications based on feedback, questions, and subsequent email discussions. A final draft was then circulated to all members for additional email discussion and to ensure consensus.
| RESULTS
| Consensus definition of new-onset refractory status epilepticus
New-onset refractory status epilepticus is a clinical presentation, not a specific diagnosis, in a patient without active epilepsy or other preexisting relevant neurological disorder, with new onset of refractory status epilepticus without a clear acute or active structural, toxic, or metabolic cause.
| Explanatory notes
• Most of the common acute or active structural, toxic, or metabolic etiologies can be identified in the first few hours, but it may take up to 72 hours to rule out some structural lesions, drug overdoses, and metabolic conditions due to delays in obtaining imaging and laboratory results.
• NORSE includes patients with viral infections (including herpes simplex virus-1 [HSV-1]) and autoimmune syndromes of new onset, even if these are diagnosed in the initial 72 hours (including anti-NMDA encephalitis). Thus, these more specific diagnoses can present as NORSE.
o Although we initially planned to exclude HSV-1, research has shown that HSV-1 only rarely (if ever) presents with refractory status epilepticus. For example, in the California Encephalitis Project, of 1151 cases of encephalitis, only 43 (4%) had refractory status epilepticus, and none of those had HSV-1 detected. 20 We decided not to exclude any specific viruses as we do not want the definition to vary based on the ability to identify viruses in different centers, or to vary over the years as we improve our ability to detect viruses. In addition, the causal role of positive testing for certain viruses may be unclear. Thus, patients with these positive results can present as NORSE and should still be included in research on NORSE. o The reasoning was similar for including patients with autoimmune syndromes, regardless of how quickly they are diagnosed. Most cannot be diagnosed quickly enough to affect early management decisions. We do not want the determination of the clinical presentation of NORSE to depend on the speed and accuracy of the local laboratories, or to change over the years as these results are obtained more quickly or as more antibodies are discovered. Furthermore, the direct causal role of many of these antibodies remains unclear and should be studied further (eg, anti-thyroid peroxidase, low titer anti-glutamic acid decarboxylase, or anti-voltage-gated potassium channel complex without anti-leucine-rich, glioma inactivated 1 protein or contactin-associated protein-like 2). Thus, these antibodies can be associated with (and potentially cause) the clinical presentation of NORSE.
Finally there is evidence that NORSE that remains unexplained and NORSE found to have an autoimmune etiology are similar in most aspects, including cerebrospinal fluid (CSF) profiles, at least based on 1 study of 125 cases.
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• NORSE includes patients with remote brain injuries and patients with resolved epilepsy (seizure-free for 10 years and off medication for >5 years 21 ). Those with active epilepsy are excluded.
• A determination of NORSE requires imaging, CSF analysis, toxicology assessment, and other blood tests as recommended for evaluation of status epilepticus in other guidelines and reviews. 19, [22] [23] [24] • NORSE typically presents as super-refractory status epilepticus (see definition below), but this is not required to qualify as NORSE.
• "Cryptogenic NORSE" or "NORSE of unknown etiology" subgroup: This term applies to patients with the clinical presentation of NORSE, but in whom the cause remains unknown after extensive workup (which may take several weeks to complete). This term is already in use in the literature in this manner.
16,25-27
• NORSE does not include refractory status epilepticus with fully retained consciousness such as epilepsia partialis continua.
| Consensus definition of febrile infectionrelated epilepsy syndrome
Febrile infection-related epilepsy syndrome is a subcategory of NORSE that requires a prior febrile infection, with fever starting between 2 weeks and 24 hours prior to onset of refractory status epilepticus, with or without fever at onset of status epilepticus.
| Explanatory notes
• FIRES includes all ages.
• This definition of FIRES excludes most cases of febrile status epilepticus in children (prolonged febrile convulsions), as febrile seizures usually occur in children who have onset of fever <24 hours prior to onset of seizures or whose fever is recognized only after the onset of seizures. 28 Although this definition may include some unusual cases of "febrile status epilepticus" when fever has been present for >24 hours and the status epilepticus is refractory, this situation may reflect a pathophysiology similar to that of other cases presenting with NORSE, albeit on the mild end of the spectrum. Further research is necessary to determine if these self-limited cases and more typical cases of NORSE have distinct or overlapping etiologies and pathophysiologies.
| Consensus definition of infantile hemiconvulsion-hemiplegia and epilepsy syndrome
Infantile hemiconvulsion-hemiplegia and epilepsy syndrome is a specific syndrome in a patient <2 years old, presenting as NORSE with unilateral motor seizures, highgrade fever at the time of onset of refractory status epilepticus, and unilaterally abnormal acute imaging, followed by hemiparesis lasting at least 24 hours, and excluding definite infectious encephalitis.
| Explanatory note
• As this syndrome of IHHE presents as NORSE and has no clear definition in the literature, we felt it would be useful to include a proposed definition in this manuscript.
| Consensus definitions for status epilepticus subtypes
The following terms have been defined previously, but sometimes in variable ways. We have kept the most commonly used definitions, and put them in this document for convenience as they are closely related to the definition of NORSE. We also newly define the term "prolonged" as a modifier for refractory SE and super-refractory SE.
• Refractory SE (RSE): SE persisting despite administration of at least 2 appropriately selected and dosed parenteral medications including a benzodiazepine. There is no specific seizure duration required.
• Super-Refractory SE (SRSE): SE persisting at least 24 hours after onset of anesthesia, either without interruption despite appropriate treatment with anesthesia; recurring while on appropriate anesthetic treatment; or recurring after withdrawal of anesthesia and requiring anesthetic reintroduction. This is consistent with the recent literature. 29, 30 "Anesthesia" includes commonly used agents such as midazolam, propofol, pentobarbital, thiopental, ketamine, and others, so long as they are used at anesthetic doses.
• Prolonged RSE (PRSE): RSE that persists for at least 7 days despite appropriate management, but without use of anesthetics.
• Prolonged SRSE (PSRSE): SRSE that persists for at least 7 days, including ongoing need for anesthetics.
The definitions in this manuscript were reviewed and fully endorsed by the Critical Care EEG Monitoring Research Consortium (CCEMRC) on 11/15/2017. The CCEMRC is an international consortium of more than 50 member centers dedicated to multicenter research to improve diagnosis and treatment of critically ill adults and children by harnessing neurophysiologic monitoring. See https://www.acns.org/research/critical-care-eeg-monitoringresearch-consortium-ccemrc for further details on the CCEMRC.
| CONCLUSION
We hope these definitions will improve communication for clinicians, researchers, families, and patients. We expect that these definitions will broaden the use of these terms to some degree, such as including less refractory cases (refractory, but not super-refractory). This will help enable investigators to answer questions such as why some patients become super-refractory; whether NORSE preceded by a febrile infection (ie, FIRES) is different than other cases of NORSE; whether etiologies and responses to treatments differ by age; if and when early immune treatment is beneficial; and many other questions.
